Evogene Statistics
Total Valuation
Evogene has a market cap or net worth of $30.34 million. The enterprise value is $15.07 million.
| Market Cap | 30.34M |
| Enterprise Value | 15.07M |
Important Dates
The next estimated earnings date is Thursday, August 15, 2024, before market open.
| Earnings Date | Aug 15, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Evogene has 50.58 million shares outstanding.
| Shares Outstanding | 50.58M |
| Owned by Insiders (%) | 1.66% |
| Owned by Institutions (%) | 8.19% |
| Float | 46.65M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.30 |
| Forward PS | 2.08 |
| PB Ratio | 3.66 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.64 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.06, with a Debt / Equity ratio of 1.37.
| Current Ratio | 5.06 |
| Quick Ratio | 4.94 |
| Debt / Equity | 1.37 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -35.19 |
Financial Efficiency
Return on equity (ROE) is -161.60% and return on invested capital (ROIC) is -121.21%.
| Return on Equity (ROE) | -161.60% |
| Return on Assets (ROA) | -41.10% |
| Return on Capital (ROIC) | -121.21% |
| Revenue Per Employee | $64,711 |
| Profits Per Employee | -$151,204 |
| Employee Count | 142 |
| Asset Turnover | 0.18 |
| Inventory Turnover | 2.57 |
Taxes
In the past 12 months, Evogene has paid $12,000 in taxes.
| Income Tax | 12,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -46.45% in the last 52 weeks. The beta is 1.07, so Evogene's price volatility has been similar to the market average.
| Beta (5Y) | 1.07 |
| 52-Week Price Change | -46.45% |
| 50-Day Moving Average | 0.67 |
| 200-Day Moving Average | 0.71 |
| Relative Strength Index (RSI) | 37.72 |
| Average Volume (20 Days) | 101,946 |
Short Selling Information
| Short Interest | 62,359 |
| Short Previous Month | 53,577 |
| Short % of Shares Out | 0.12% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.03 |
Income Statement
In the last 12 months, Evogene had revenue of $9.19 million and -$21.47 million in losses. Loss per share was -$0.46.
| Revenue | 9.19M |
| Gross Profit | 7.51M |
| Operating Income | -23.80M |
| Pretax Income | -21.46M |
| Net Income | -21.47M |
| EBITDA | -18.22M |
| EBIT | -20.87M |
| Loss Per Share | -$0.46 |
Balance Sheet
The company has $26.61 million in cash and $11.34 million in debt, giving a net cash position of $15.27 million or $0.30 per share.
| Cash & Cash Equivalents | 26.61M |
| Total Debt | 11.34M |
| Net Cash | 15.27M |
| Net Cash Per Share | $0.30 |
| Equity (Book Value) | 8.29M |
| Book Value Per Share | 0.16 |
| Working Capital | 24.89M |
Cash Flow
In the last 12 months, operating cash flow was -$19.44 million and capital expenditures -$557,000, giving a free cash flow of -$20.00 million.
| Operating Cash Flow | -19.44M |
| Capital Expenditures | -557,000 |
| Free Cash Flow | -20.00M |
| FCF Per Share | -$0.40 |
Margins
Gross margin is 81.72%, with operating and profit margins of -258.98% and -233.66%.
| Gross Margin | 81.72% |
| Operating Margin | -258.98% |
| Pretax Margin | -233.53% |
| Profit Margin | -233.66% |
| EBITDA Margin | -198.32% |
| EBIT Margin | -227.08% |
| FCF Margin | -217.65% |
Dividends & Yields
Evogene does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -22.02% |
| Shareholder Yield | -22.02% |
| Earnings Yield | -70.77% |
| FCF Yield | -65.92% |
Analyst Forecast
The average price target for Evogene is $3.62, which is 503.43% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $3.62 |
| Price Target Difference | 503.43% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on November 19, 2013. It was a reverse split with a ratio of 1:2.
| Last Split Date | Nov 19, 2013 |
| Split Type | Reverse |
| Split Ratio | 1:2 |
Scores
Evogene has an Altman Z-Score of -7.61 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -7.61 |
| Piotroski F-Score | 4 |